At the recent ARVO meeting, Daniela Braz presented the latest findings from INSERM on the development of a new eye drop to treat cornea wounds in mice.
restorevision@catalyze-group.com
Exploring the use of spironolactone to treat diseases of the cornea – Study by INSERM
At the recent ARVO meeting, Raquel Gregorio presented the latest findings from INSERM on the use of spironolactone for treating corneal diseases.
A novel combination treatment offers promise for corneal vessel regression and longer graft survival – Study by UKK
At the recent ARVO meeting, Meert Mestanoglu presented UKK’s ongoing research on a novel combination treatment for corneal vessel regression.
Restore Vision partner KOL hosts Olisens symposium at SFO Congress
Restore Vision partner’s KOL host symposium on SFO 2024 and explored the use of Olisens on the treatment of Corneal Neovessels
Restore Vision at ARVO Conference in Seattle
The Restore Vision Consortium had a significant presence at the ARVO 2024 “Vision for the Future” conference from 05th-09th May 2024 in Seattle, Washington to present our work on new therapies for rare ocular diseases.
A new eyedrop formulation of spirolactone helps corneal wound healing in rats
Learn more about Restore Vision’s preliminary results on a new eyedrop formulation.
Restore Vision’s Ethics Advisor
Restore Vision is thrilled to welcome its new Ethics Advisor, Dr. Helen Busby, who will support the development and review of ethics applications for the project’s research involving human subjects.